Organic
有机的
基本信息
- 批准号:8335542
- 负责人:
- 金额:$ 3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-07-21 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:AffinityAreaBindingBiological ProcessCalendarCellsChemicalsComprehensive Cancer CenterConsultConsultationsCustomDNADevelopmentDoctor of PhilosophyFox Chase Cancer CenterFoxesFundingGrantInstructionLabelLeadershipLigandsMalignant NeoplasmsMissionOrganic Synthesis FacilityPeer ReviewPharmaceutical PreparationsPhotosensitizing AgentsProdrugsProductivityProtein BindingProteinsPublicationsReagentResearchResearch PersonnelResearch Project GrantsSeasonsSeriesServicesSpecificityStaining methodStainsStructureSystemTamoxifenanalogantibody conjugateanticancer researchbiological researchchemical synthesiscompound 17cost effectivecrosslinkenzyme activityenzyme mechanismenzyme substrate analoginhibitor/antagonistlink proteinmacromoleculemeetingsnovelprogramsprotein functionsmall molecule
项目摘要
The primary purpose of the Organic Synthesis Facility (OSF) is to produce the highest quality synthetic molecules for Fox Chase Cancer Center (FCCC) investigators. The OSF was used by 19 investigators with peer-reviewed funding in calendar year 2009. Over eighty-five percent (85.4%) of use was in support of peer-reviewed, funded investigators in calendar year 2009. Small organic molecules are used in many areas
of research as specific reagents including those that are inhibitors of enzyme activity or protein binding.
Some of these molecules have been used in the development of prodrugs against target proteins identified at FCCC. Analogues of natural substrates have been used to probe enzyme mechanism, to investigate protein function, or to lest specific hypotheses. The molecules synthesized by the Facility are not purchasable from chemical companies, and custom synthesis from commercial enterprises is either not available or prohibitively expensive. The demand for synthetic services and especially the demand for novel
compound synthesis have increased significantly over this current funding period. In order to meet this need, the efficiency and productivity of the Facility have been increased with the addition of a seasoned Ph.D. chemist to the staff and by acquisition of a new LC-MS system. In addition to increasing efficiency, the LC-MS system provides the Facility with new capabilities and services. During the last grant period
(calendar years 2006-2009), 79 different chemical syntheses were completed including 44 novel compounds for 17 investigators in four Research Programs. The compounds synthesized were very diverse in structure and included a series of tamoxifen analogues, drug-conjugated antibodies, p53 inhibitors, Paki inhibitors, and photosensitizers. The OSF provided analytical, purification and consulting services to 46 investigators from all five Research Programs and seven Shared Facilities during the current funding period. In the last four calendar years (2006-2009), the average number of requests for these analytical and purification services was 59 per month, compared to 34 in calendar years 2000-2004. The large user group of 46 investigators from all five Research Programs and seven Shared Facilities indicates that the materials
produced and services provided by the Facility are necessary for the scientific objectives of a wide range of research projects being carried out throughout the Center.
有机合成设施(OSF)的主要目的是为Fox Chase Cancer Center(FCCC)研究人员生产最高质量的合成分子。 OSF在2009年日历年中由19名与同行评审资金进行的调查人员使用。超过85%(85.4%)的使用用于2009年日历年的同行评审,资助的研究人员。
作为特定试剂,包括酶活性或蛋白质结合的特定试剂。
其中一些分子已用于针对FCCC鉴定的靶蛋白的前药的开发。天然底物的类似物已用于探测酶机制,研究蛋白质功能或害怕特定的假设。该设施合成的分子无法从化学公司购买,商业企业的定制合成是不可用的,要么昂贵。对合成服务的需求,尤其是对新颖的需求
在当前的资金期间,复合合成显着增加。为了满足这一需求,随着经验丰富的博士学位的增加,设施的效率和生产率已提高。化学家向工作人员和获得新的LC-MS系统。除了提高效率外,LC-MS系统还为设施提供了新的功能和服务。在最后一个赠款期间
(日历年2006- 2009年),完成了79种不同的化学合成,其中包括四个研究计划中17名研究人员的44种新颖化合物。合成的化合物在结构上非常多样化,包括一系列他莫昔芬类似物,药物偶联的抗体,p53抑制剂,PAKI抑制剂和光敏剂。 OSF在当前资助期间为来自所有五个研究计划和七个共享设施的46名调查人员提供了分析,净化和咨询服务。在过去的四个日历年(2006-2009)中,这些分析和纯化服务的平均请求数为每月59,而2000- 2004年日历年为34。来自所有五项研究计划和七个共享设施的46位调查人员的大型用户组表明材料
该设施提供的生产和服务对于整个中心进行的广泛研究项目的科学目标是必需的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL V. SEIDEN其他文献
MICHAEL V. SEIDEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL V. SEIDEN', 18)}}的其他基金
相似国自然基金
定向金属结合区域的倒捻子素类PDE4抑制剂:类药性优化及抗肺纤维化作用研究
- 批准号:22277019
- 批准年份:2022
- 资助金额:54.00 万元
- 项目类别:面上项目
定向金属结合区域的倒捻子素类PDE4抑制剂:类药性优化及抗肺纤维化作用研究
- 批准号:
- 批准年份:2022
- 资助金额:54 万元
- 项目类别:面上项目
高光谱遥感与地面观测数据结合的区域甘蔗糖分估算研究
- 批准号:42105175
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
ERβ结合区域遗传变异与结直肠癌发病风险的机制研究
- 批准号:
- 批准年份:2020
- 资助金额:57 万元
- 项目类别:面上项目
基于“区域资源高效协同机制”作用的医养结合养老社区中医疗功能空间配置研究
- 批准号:
- 批准年份:2020
- 资助金额:58 万元
- 项目类别:面上项目
相似海外基金
Accelerating drug discovery via ML-guided iterative design and optimization
通过机器学习引导的迭代设计和优化加速药物发现
- 批准号:
10552325 - 财政年份:2023
- 资助金额:
$ 3万 - 项目类别:
Inducing Off-pathway Assembly of HIV Gag Polyprotein with Computationally Designed Peptides
用计算设计的肽诱导 HIV Gag 多蛋白的非途径组装
- 批准号:
10724495 - 财政年份:2023
- 资助金额:
$ 3万 - 项目类别:
Diagnostic aptamer reagents to develop multi-analyte blood test for pre-clinical, mild and moderate Alzheimer's disease
诊断适体试剂用于开发针对临床前、轻度和中度阿尔茨海默病的多分析物血液检测
- 批准号:
10597840 - 财政年份:2023
- 资助金额:
$ 3万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 3万 - 项目类别:
Planning Study for the Development of Sigma 2 ligands as Analgesics
Sigma 2 配体镇痛药开发规划研究
- 批准号:
10641500 - 财政年份:2023
- 资助金额:
$ 3万 - 项目类别: